Compare OOMA & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OOMA | ORGO |
|---|---|---|
| Founded | 2003 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 408.2M | 348.6M |
| IPO Year | 2015 | 2016 |
| Metric | OOMA | ORGO |
|---|---|---|
| Price | $17.75 | $2.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $18.77 | $8.50 |
| AVG Volume (30 Days) | 220.1K | ★ 1.8M |
| Earning Date | 05-27-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 188.46 | ★ 1600.00 |
| EPS | ★ 0.23 | 0.15 |
| Revenue | $114,490,000.00 | ★ $564,169,000.00 |
| Revenue This Year | $20.35 | N/A |
| Revenue Next Year | $4.17 | $26.27 |
| P/E Ratio | $71.00 | ★ $15.57 |
| Revenue Growth | 9.53 | ★ 17.04 |
| 52 Week Low | $9.79 | $2.21 |
| 52 Week High | $16.89 | $7.08 |
| Indicator | OOMA | ORGO |
|---|---|---|
| Relative Strength Index (RSI) | 80.02 | 57.30 |
| Support Level | $10.95 | $2.26 |
| Resistance Level | N/A | $4.12 |
| Average True Range (ATR) | 0.56 | 0.14 |
| MACD | 0.14 | 0.03 |
| Stochastic Oscillator | 98.71 | 88.61 |
Ooma Inc is a communications services company. It is a smart software-as-a-service (SaaS) and unified communications platform that deliver voice and collaboration features including messaging, intelligent virtual attendants and video conferencing, and residential phone service provides PureVoice high-definition voice quality, advanced functionality and integration with mobile devices. Its services rely upon the following main elements: multi-tenant cloud service, on-premise devices, desktop and mobile applications, and calling platforms. It generates revenues from the sale of subscriptions and other services.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.